Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 1 completion103d agoCheng Du Sheng Nuo Biotec Co Ltd — CIGB-814 (Phase I Trial Completion)CIGB-814

Therapy area: Immunology. Indication: Rheumatoid Arthritis

Apr 30, 2026phase 1 completion103d agoIlife Consulting Sarl — PST-611 (Phase I Trial Completion)PST-611

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

full page →PST-611 →source: globaldata

Apr 30, 2026phase 1 completion103d agoEcolab Inc — (acetaminophen + ibuprofen) (Phase I Trial Completion)(acetaminophen + ibuprofen)

Therapy area: Central Nervous System, Ear Nose Throat Disorders, Hormonal Disorders, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Ankylosing Spondylitis (Bekhterev's Disease), Dental Pain (Toothache/Tooth Pain), Fever, Fibromyalgia (Fibromyalgia Syndrome), Gouty Arthritis (Gout), Hyperthyroidism, Laryngitis, Low Back Pain, Mixed Pain (Nociceptive Pain/Neuropathic Pain), Musculoskeletal Inflammation, Musculoskeletal Pain, Myalgia (Muscle Pain), Neuropathic Pa

full page →(acetaminophen + ibuprofen) →source: globaldata

Apr 30, 2026phase 1 completion103d agoBeijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)pneumococcal (20-valent) vaccine

Therapy area: Respiratory. Indication: Streptococcal Pneumonia

full page →pneumococcal (20-valent) vaccine →source: globaldata

Apr 30, 2026phase 1 completion103d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

Therapy area: Immunology. Indication: Inflammation

full page →FT-2109 →source: globaldata

Apr 30, 2026phase 1 completion103d agoAvance Clinical Pty Ltd — FT-2109 (Phase I Trial Completion)FT-2109

Therapy area: Immunology. Indication: Inflammation

full page →FT-2109 →source: globaldata

Apr 30, 2026phase 1 completion103d agoInsignis Therapeutics Inc — HLK-0006 (Phase I Trial Completion)HLK-0006

Therapy area: Immunology. Indication: Anaphylaxis, Food Allergy, Peanut Allergy

full page →HLK-0006 →source: globaldata

Apr 30, 2026phase 1 initiation103d agoNanjing IASO Biotherapeutics Co Ltd — IASO-782 (Phase I Trial Initiation)IASO-782

Therapy area: Immunology. Indication: Systemic Lupus Erythematosus

full page →IASO-782 →source: globaldata

Apr 30, 2026phase 1 2 completion103d agoEyebiotech Ltd — MK-8748 (Phase I/II Trial Completion)MK-8748

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Branch Retinal Vein Occlusion, Diabetic Macular Edema, Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration

full page →MK-8748 →source: globaldata

Apr 30, 2026phase 1 2 completion103d agoWuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)M-701

Therapy area: Oncology, Respiratory. Indication: Malignant Pleural Effusion, Non-Small Cell Lung Cancer

full page →M-701 →source: globaldata

Apr 30, 2026phase 2 completion103d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →UA-021 →source: globaldata

Apr 30, 2026phase 2 completion103d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →telitacicept →source: globaldata

Apr 30, 2026phase 2 completion103d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

full page →autologous regulatory T cells →source: globaldata

Apr 30, 2026phase 2 completion103d agoBrigham and Women's Hospital — dupilumab (Phase II Trial Completion)dupilumab

Therapy area: Ear Nose Throat Disorders, Respiratory. Indication: Asthma, Nasal Polyps (Nasal Polyposis), Rhinosinusitis

full page →dupilumab →source: globaldata

Apr 30, 2026phase 2 completion103d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

full page →tulisokibart →source: globaldata

Apr 30, 2026phase 2 completion103d agoShenzhen Eye Hospital — umbilical cord mesenchymal stem cells derived apoptotic vesicles (Phase II Trial Completion)umbilical cord mesenchymal stem cells derived apoptotic vesicles

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye)

full page →umbilical cord mesenchymal stem cells derived apoptotic vesicles →source: globaldata

Apr 30, 2026phase 2 completion103d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata

Apr 30, 2026phase 2 completion103d agoAstraZeneca Plc — tozorakimab (Phase II Trial Completion)tozorakimab

Therapy area: Respiratory. Indication: Chronic Obstructive Pulmonary Disease (COPD)

full page →tozorakimab →source: globaldata

Apr 30, 2026phase 2 completion103d agoRenji Hospital — norepinephrine (Phase II Trial Completion)norepinephrine

Therapy area: Genito Urinary System, Immunology. Indication: Delayed Graft Function (DGF), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

full page →norepinephrine →source: globaldata

Apr 30, 2026phase 2 completion103d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

Therapy area: Immunology. Indication: Inflammation

full page →SSJG-009 →source: globaldata

Apr 30, 2026phase 2 completion103d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

Therapy area: Respiratory. Indication: Cough

full page →LIDOCAINE →source: globaldata

← prev

page 2 of 2

Week of Apr 27, 2026